Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of S1P receptor inhibitor in preparing product for preventing and treating ankylosing spondylitis

An ankylosing spondylitis, receptor inhibitor technology, applied in the field of medicine and biology, can solve the problems of not being able to block the occurrence of pathological osteogenesis in patients, and there is no effective method for excessive osteogenesis.

Pending Publication Date: 2021-02-09
中山大学附属第八医院
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment of AS is mainly to relieve inflammation, but as the disease progresses, even if the inflammation is well controlled, it still cannot block the occurrence of pathological osteogenesis in patients, and there is no effective method for the treatment of excessive osteogenesis in AS.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of S1P receptor inhibitor in preparing product for preventing and treating ankylosing spondylitis
  • Use of S1P receptor inhibitor in preparing product for preventing and treating ankylosing spondylitis
  • Use of S1P receptor inhibitor in preparing product for preventing and treating ankylosing spondylitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Animal Experiments: Effects of S1P Receptor Inhibitors on Pathological Osteogenesis and Spinal Fusion in Mice

[0027] The process of animal experimentation is as follows figure 1 Shown:

[0028] (1) Mouse model

[0029] SKG mice, developed by Japan's CLEA Company, have a genetic mutation in the SH2 domain of ZAP-70 (a key signal transduction molecule in T cells). Due to the disorder of T cell signal transduction, the excessive proliferation of inflammatory T cells in SKG mice results in systemic chronic arthritis and extra-articular manifestations. About 2 weeks after a single induction with curdlan, the mice developed systemic multiple arthritis and abnormal bone metabolism, and developed spinal fusion about 8 weeks after induction. Because the phenotype is similar to the clinical manifestations of AS patients, it is widely used as a disease model of AS.

[0030] The SKG mice used in this experiment were all purchased from CLEA, Japan. When the mice were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the technical field of medical biology, particularly relates to use of an S1P receptor inhibitor in preparing a product for preventing and treating ankylosing spondylitis, and aims to solve a problem that pathological osteogenesis fusion of joints and spines of a patient cannot be solved by AS treatment at present. An inhibition of H angiogenesis is used as a means. By inhibiting functions of S1P receptors, pathological osteogenesis is inhibited, meanwhile, joint ankylosis and spinal fusion are delayed, so that new AS treatment targets are obtained through exploration, and a new direction is provided for preventing and treating ankylosing spondylitis.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and specifically relates to the application of S1P receptor inhibitors in the preparation of products for the prevention and treatment of ankylosing spondylitis. Background technique [0002] Ankylosing spondylitis (AS), a seronegative spondyloarthropathy, is an autoimmune disease characterized by inflammation involving the spine and sacroiliac joints. It is more common in males and mainly affects young adults, usually around the age of 18-22. The incidence rate in my country is relatively high. The clinical manifestations of AS patients are inflammatory low back pain, stiffness and limited mobility, and some patients may have extra-articular manifestations such as uveitis. Because the long-term chronic inflammation in the body can involve synovial joints, cartilage joints, and the parts where tendons and ligaments attach to bones, patients can rapidly progress to bony ankylosis, ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61P19/08A23L33/00
CPCA61K45/00A61P19/08A23L33/00
Inventor 沈慧勇马梦君米汝佳李鸿宇杨文王鹏吴燕峰卢艺萱
Owner 中山大学附属第八医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com